194 related articles for article (PubMed ID: 25133546)
21. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
[TBL] [Abstract][Full Text] [Related]
22. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma.
Smith RA; Bosonnet L; Ghaneh P; Raraty M; Sutton R; Campbell F; Neoptolemos JP
Dig Surg; 2008; 25(3):226-32. PubMed ID: 18577869
[TBL] [Abstract][Full Text] [Related]
23. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
24. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
25. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
Cancer Sci; 2011 Sep; 102(9):1673-9. PubMed ID: 21615621
[TBL] [Abstract][Full Text] [Related]
27. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
28. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
29. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
[TBL] [Abstract][Full Text] [Related]
30. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
[TBL] [Abstract][Full Text] [Related]
31. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
32. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
33. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract][Full Text] [Related]
34. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
35. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
[TBL] [Abstract][Full Text] [Related]
36. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment Serum Uric Acid as an Efficient Predictor of Prognosis in Men with Laryngeal Squamous Cell Cancer: A Retrospective Cohort Study.
Hsueh CY; Shao M; Cao W; Li S; Zhou L
Oxid Med Cell Longev; 2019; 2019():1821969. PubMed ID: 31178950
[TBL] [Abstract][Full Text] [Related]
38. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
39. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
[TBL] [Abstract][Full Text] [Related]
40. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
Nakagawa S; Yamashita YI; Umezaki N; Yamao T; Okabe H; Imai K; Nitta H; Hashimoto D; Chikamoto A; Baba H
Pancreas; 2018 Oct; 47(9):1130-1134. PubMed ID: 30161074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]